Avanos Medical Inc (N:AVNS)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 5405 Windward Parkway, Suite 100 South ALPHARETTA GA 30004 |
| Tel: | N/A |
| Website: | https://avanos.com |
| IR: | See website |
| Key People | ||
| Joseph F. Woody Chief Executive Officer, Director | Michael C. Greiner Chief Financial Officer, Senior Vice President, Chief Transformation Officer | Mojirade James Senior Vice President, General Counsel, Secretary |
| Kerr W. Holbrook Senior Vice President, Chief Commercial Officer | Sudhakar Varshney Senior Vice President - Global Supply Chain and Procurement | |
| Business Overview |
| Avanos Medical, Inc. is a medical device company, which is focused on delivering solutions. The Company offers healthcare needs, such as providing nutrition to patients from hospital to home and reducing the use of opioids while helping patients move from surgery to recovery. The Company conducts its business in one segment that provides its medical device products to healthcare providers and patients globally with manufacturing facilities in the United States and Mexico. Its digestive health products include MIC-KEY enteral feeding tubes, Corpak patient feeding solutions and NeoMed neonatal and pediatric feeding solutions. The Company's acute pain products include ON-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems. The Company's interventional pain solutions include COOLIEF pain therapy and OrthogenRxs knee osteoarthritis pain relief injection products. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Avanos Medical Inc revenues decreased 2% to $673.3M. Net loss before extraordinary items totaled $9.9M vs. income of $21.5M. Revenues reflect Pain Management segment decrease of 12% to $301.7M, North America segment decrease of 3% to $537.9M, Asia Pacific and Latin America segment decrease of 6% to $51.3M. Net loss reflects Other expense, net increase from $3M to $13.3M (expense). |
| Employees: | 3,771 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $947.09M as of Dec 31, 2023 |
| Annual revenue (TTM): | $673.30M as of Dec 31, 2023 |
| EBITDA (TTM): | $97.80M as of Dec 31, 2023 |
| Net annual income (TTM): | -$9.90M as of Dec 31, 2023 |
| Free cash flow (TTM): | $14.60M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $80.30M as of Dec 31, 2023 |
| Shares outstanding: | 46,204,099 as of Mar 1, 2024 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.